Bibliography
- RIORDAN JR, ROMMENS JM, KEREM B et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 245(4922):1066–1073.
- ZEITLIN PL: Emerging drug treatments for cystic fibrosis. Expert Opin. Emerging Drugs (2003) 8(2):523–535.
- SINGH AK, SCHULTZ BD, VAN DRIESSCHE W, BRIDGES RJ: Transepithelial fluctuation analysis of chloride secretion]. Cyst. Fibros. (2004) 3\(Supp1.2):127–132.
- GRIBKOFF VK, CHAMPIGNY G, BARBRY P et al.: The substituted benzimidazolone N5004 is an opener of the cystic fibrosis chloride channel. J. Biol. Chem. (1994) 269(15):10983–10986.
- DERAND R, BULTEAU-PIGNOUX L, BECQ F: Comparative pharmacology of the activity of wild type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative N5004. Membr. Biol. (2003) 194(2):109–117.
- DEVOR DC, BRIDGES RJ, PILEWSKI JM: Pharmacological modulation of ion transport across wild type and 8E508 CFTR-expressing human bronchial epithelia. Am. J. Physiol. Cell PhysioL (2000) 279(2):C461–C479.
- AL-NAKKASH L, HU S, LI M, HWANG TC: A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs. J. Pharmacol Exp. Ther. (2001) 296(2):464–472.
Websites
- http://www.cff.org/about_cf/what_is_cfI What is CF?—CF Fdn.
- http://www.cff.org/research/ cf research_in_the_news/index.cfm?ID 26418cblnShowBack False8cidContentType 1213 CF Research in the News — CF Fdn.
- http://www.vrtx.com/Pressreleases 192004/ pr060904.html Vertex Pharm., Inc. CF press release.